Baird Remains Buyers of Biogen (BIIB) Despite Kyle Bass Tecfidera Challenge

PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients

Interim Results from Phase 3 Extension Study Affirm PLEGRIDYs Safety Profile and Robust Effect on Clinical, MRI, and NEDA Outcomes

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Today Biogen (NASDAQ: BIIB) announced new data from the ATTAIN study which demonstrate the long-term safety and efficacy of PLEGRIDY® (peginterferon beta-1a) over three years in people with relapsing-remitting... More

International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction

Many Factors Influence Patient Satisfaction with MS Therapy

Physicians and Patients Agree that Patient Input into Treatment Decisions Correlates with Patient Satisfaction

Findings Highlight Need for Physicians to Understand Individual Patient Treatment Priorities

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- New findings from an international survey of people living with multiple sclerosis (MS) and neurologists show that multiple factors in the patient-physician dynamic contribute to overall patient treatment satisfaction, including patients treatment expectations, degree of input into the treatment decision-making process and communication with their physicians. The results reinforce the significance... More

TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients

TECFIDERA Provides Robust and Long-Term Efficacy in Treatment-Naïve Patients and Those with Prior Interferon or Glatiramer Acetate Experience

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen (NASDAQ: BIIB) today announced new data that continue to support TECFIDERA® (dimethyl fumarate) as an effective, long-term... More